The impact of IDH2 mutant allele (R140/R172) on survival outcomes with enasidenib: An update from the IDHENTIFY trial

Mutations in the isocitrate dehydrogenase 2 (IDH2) gene occur in around 8–19% of...

2022 ASCO Annual Meeting roundup – Ivosidenib

We summarize three poster presentations from the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, which covered safety data on Ivo +...

Can pre-transplant MRD testing predict patients who are more likely to relapse?

During ASCO we spoke with Christopher Hourigan, National Institutes of Health, Bethesda, US. We asked, Can...

How could new treatment options improve outcomes in FLT3-mutated AML?

During the 2022 ASCO Annual Meeting, the AML Hub spoke with Naval Daver, MD Anderson Cancer Center, Houston, US. We asked, How...

Does 10-day decitabine improve post-transplant outcomes in older patients compared with 3+7 chemo?

Ossenkoppele begins by introducing the study presented at the congress, outlining the study design...

The QuANTUM-First study

The AML Hub was pleased to speak with Hee-Je Kim, The Catholic University of Korea, Seoul, KR. Kim discussed the QuANTUM-First study.

What is the clinical significance of secondary-AML-type mutations in de novo AML?

During the EHA 2022 Congress, the AML Hub spoke with Isolda Fernandez, FUNDALEU, Buenos Aires, AR. We asked, What is...

What is the clinical significance of co-mutational patterns in AML?

During the EHA 2022 Congress, the AML Hub spoke with Brian Huntly, University of Cambridge, Cambridge, UK. We asked, What is the...

Neutralizing antibody responses to SARS-CoV-2 in patients with AML or MDS

Severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) represents an increased risk for patients with immune dysfunction...

Should COVID-19 vaccination be postponed after AML therapy?

During the 63rd ASH Annual Meeting and Exposition, the AML hub spoke with Sabine Haggenburg, Amsterdam UMC, Amsterdam, NL. We asked, Should...

EPICOVIDEHA registry: Epidemiology and outcomes in patients with hematologic malignancies infected with COVID-19

Patients with hematologic malignancies (HMs) may have intensified immune dysregulation...

Severity of SARS-CoV-2 infection and the safety of COVID-19 vaccination in patients receiving HSCT

The coronavirus pandemic has put a great strain on worldwide healthcare systems. Patients with...

What is the clinical significance of secondary-AML-type mutations in de novo AML?

During the EHA 2022 Congress, the AML Hub spoke with Isolda Fernandez, FUNDALEU, Buenos Aires, AR. We asked, What is...

TP53-mutated complex karyotype in patients with de novo or therapy-related MDS and AML

Identifying TP53-mutated complex karyotypes in myeloid neoplasms as a separate, highly aggressive entity will aid...

Molecular analysis of TP53-mutant AML and MDS-EB

The presence of TP53 mutations in acute myeloid leukemia (AML) and myelodysplastic syndromes with excess blasts (MDS-EB) has been identified as a...

Patients with poor risk cytogenetics and TP53wt treated with venetoclax and HMA show increases in overall survival compared to treatment with azacitidine only

Patients with acute myeloid leukemia...